Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A potentially registrational trial of trial for darovasertib in neoadjuvant UM setting

Next Previous
Search
Trial Profile

A potentially registrational trial of trial for darovasertib in neoadjuvant UM setting

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darovasertib (Primary)
  • Indications Uveal melanoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 14 Apr 2025 According to an IDEAYA Biosciences media release, Company announced a successful FDA Type D meeting on the Phase 3 registrational trial design that will assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma (UM).
  • 31 Mar 2025 According to an IDEAYA Biosciences media release, study would evaluate neoadjuvant darovasertib in primary UM patients who are eligible for enucleation (Cohort 1) or plaque brachytherapy (Cohort 2).
  • 04 Nov 2024 According to an IDEAYA Biosciences media release, Following a successful Type C meeting with the U.S. Food and Drug Administration (FDA), IDEAYA is finalizing the Phase 3 registrational trial protocol and is targeting to initiate its potential registration-enabling trial in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top